JP6255382B2 - ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態 - Google Patents

ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態 Download PDF

Info

Publication number
JP6255382B2
JP6255382B2 JP2015505912A JP2015505912A JP6255382B2 JP 6255382 B2 JP6255382 B2 JP 6255382B2 JP 2015505912 A JP2015505912 A JP 2015505912A JP 2015505912 A JP2015505912 A JP 2015505912A JP 6255382 B2 JP6255382 B2 JP 6255382B2
Authority
JP
Japan
Prior art keywords
cancer
polymorph
compound
methyl
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015505912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512942A (ja
JP2015512942A5 (enExample
Inventor
クーンツ，ケビン・ウェイン
ホワン，クワン−チュン
チョイ，ヒョン・ウク
サンダース，クリステン
マチュー，スティーブン
チャンダ，アラニ
ファン，フランク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2015512942A publication Critical patent/JP2015512942A/ja
Publication of JP2015512942A5 publication Critical patent/JP2015512942A5/ja
Application granted granted Critical
Publication of JP6255382B2 publication Critical patent/JP6255382B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
JP2015505912A 2012-04-13 2013-04-11 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態 Active JP6255382B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13
US61/624,215 2012-04-13
PCT/US2013/036193 WO2013155317A1 (en) 2012-04-13 2013-04-11 Salt form of a human hi stone methyltransf erase ezh2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017198642A Division JP6634058B2 (ja) 2012-04-13 2017-10-12 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態

Publications (3)

Publication Number Publication Date
JP2015512942A JP2015512942A (ja) 2015-04-30
JP2015512942A5 JP2015512942A5 (enExample) 2016-06-09
JP6255382B2 true JP6255382B2 (ja) 2017-12-27

Family

ID=49328166

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015505912A Active JP6255382B2 (ja) 2012-04-13 2013-04-11 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態
JP2017198642A Active JP6634058B2 (ja) 2012-04-13 2017-10-12 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態
JP2018187463A Pending JP2018199740A (ja) 2012-04-13 2018-10-02 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017198642A Active JP6634058B2 (ja) 2012-04-13 2017-10-12 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態
JP2018187463A Pending JP2018199740A (ja) 2012-04-13 2018-10-02 ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態

Country Status (26)

Country Link
US (7) US9394283B2 (enExample)
EP (4) EP4190777A1 (enExample)
JP (3) JP6255382B2 (enExample)
KR (4) KR102438340B1 (enExample)
CN (2) CN108358899B (enExample)
AU (2) AU2013245878B2 (enExample)
BR (1) BR112014025508B1 (enExample)
CA (1) CA2870005C (enExample)
CY (2) CY1119383T1 (enExample)
DK (3) DK2836491T3 (enExample)
ES (3) ES2931316T3 (enExample)
HR (2) HRP20170295T1 (enExample)
HU (3) HUE031976T2 (enExample)
IL (4) IL296199B2 (enExample)
IN (1) IN2014DN09068A (enExample)
LT (2) LT2836491T (enExample)
MX (2) MX384641B (enExample)
NZ (1) NZ700761A (enExample)
PL (3) PL3184523T3 (enExample)
PT (3) PT3184523T (enExample)
RS (2) RS59392B1 (enExample)
RU (1) RU2658911C2 (enExample)
SG (3) SG11201406468YA (enExample)
SI (2) SI2836491T1 (enExample)
SM (2) SMT201900501T1 (enExample)
WO (1) WO2013155317A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018002742A (ja) * 2012-04-13 2018-01-11 エピザイム，インコーポレイティド ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
RU2699546C2 (ru) 2012-04-13 2019-09-06 Эпизайм, Инк. Комбинированная терапия для лечения рака
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
BR112015008447A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc métodos para tratar câncer
SG10201705989YA (en) 2012-10-15 2017-08-30 Epizyme Inc Substituted benzene compounds
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2910873A1 (en) 2013-04-30 2014-11-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
JP2016523955A (ja) 2013-07-10 2016-08-12 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ Ｚｅｓｔｅホモログ２エンハンサー阻害剤
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EP4324525A3 (en) 2013-10-16 2024-07-17 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
US20160228447A1 (en) * 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
WO2015077193A1 (en) * 2013-11-19 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015085325A1 (en) 2013-12-06 2015-06-11 Epizyme, Inc. Combination therapy for treating cancer
KR20230031963A (ko) 2014-06-17 2023-03-07 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
PT3157928T (pt) 2014-06-20 2019-05-30 Constellation Pharmaceuticals Inc Formas cristalinas de 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c] isoxazolo[4,5-e]azepin-4-il)acetamida
CN106794177A (zh) 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
KR20240035908A (ko) 2014-11-17 2024-03-18 에피자임, 인코포레이티드 암을 치료하기 위한 방법
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2016172199A1 (en) 2015-04-20 2016-10-27 Epizyme, Inc. Combination therapy for treating cancer
CA2988816A1 (en) 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
JP7121660B2 (ja) * 2016-06-01 2022-08-18 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
WO2018137639A1 (zh) * 2017-01-25 2018-08-02 恩瑞生物医药科技（上海）有限公司 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
CA3104209A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
BR112022012258A2 (pt) * 2019-12-20 2022-08-30 Epizyme Inc Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
NZ277556A (en) 1993-12-27 1997-06-24 Eisai Co Ltd N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
JP2002525352A (ja) 1998-09-30 2002-08-13 ザ、プロクター、エンド、ギャンブル、カンパニー ２−置換ケトアミド
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
TWI287004B (en) 2000-12-28 2007-09-21 Shionogi & Co A pyridone derivative having an affinity effect for cannabinoid 2 type receptor
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US20050101590A1 (en) 2002-02-19 2005-05-12 Kiyoshi Yasui Antipruritics
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
WO2005118796A2 (en) 2004-06-01 2005-12-15 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
DE602006019423D1 (de) 2005-06-02 2011-02-17 Univ North Carolina Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DK1940821T3 (da) 2005-10-19 2013-06-10 Gruenenthal Gmbh Nye vanilloid-receptorligander og deres anvendelse til fremstilling af lægemidler.
EP1951672B1 (en) 2005-10-21 2011-05-25 Merck Sharp & Dohme Corp. Potassium channel inhibitors
JP5078901B2 (ja) 2005-10-28 2012-11-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ＪｍｊＣドメインを含むタンパク質デメチラーゼ
US8163749B2 (en) 2005-12-14 2012-04-24 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007087015A1 (en) 2006-01-20 2007-08-02 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
CN101443007A (zh) 2006-05-15 2009-05-27 Irm责任有限公司 Terephthalamate化合物和组合物及其作为hiv整合酶抑制剂的用途
WO2007136592A2 (en) 2006-05-18 2007-11-29 Amphora Discovery Corporation 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
JP2010505958A (ja) 2006-10-10 2010-02-25 バーンハム インスティトゥート フォー メディカル リサーチ 神経防護作用組成物および方法
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
EP2215049B1 (en) 2007-10-31 2019-06-12 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
EA019974B1 (ru) 2007-12-19 2014-07-30 Кансер Рисерч Текнолоджи Лимитед 8-ЗАМЕЩЕННЫЕ ПИРИДО[2,3-b]ПИРАЗИНЫ И ИХ ПРИМЕНЕНИЕ
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2335779A1 (en) 2008-08-08 2011-06-22 New York Blood Center Small Molecule Inhibitors of Retroviral Assembly & Maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
JP2012522013A (ja) 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
WO2011082044A1 (en) 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
HRP20170736T1 (hr) * 2010-05-07 2017-07-28 Glaxosmithkline Llc Indoli
ES2534804T3 (es) 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JP6389036B2 (ja) 2010-09-10 2018-09-12 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤、およびその使用方法
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
CA2819625A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CA2867282C (en) 2012-03-12 2024-04-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
PL3184523T3 (pl) 2012-04-13 2019-12-31 Epizyme Inc Bromowodorek N-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5- (etylo(tetrahydro-2H-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'- bifenylo]-3-karboksyamidu do zastosowania w leczeniu zaburzenia proliferacji komórkowej układu hematologicznego
RU2699546C2 (ru) 2012-04-13 2019-09-06 Эпизайм, Инк. Комбинированная терапия для лечения рака
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
BR112015008447A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc métodos para tratar câncer
EP4324525A3 (en) 2013-10-16 2024-07-17 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018002742A (ja) * 2012-04-13 2018-01-11 エピザイム，インコーポレイティド ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態

Also Published As

Publication number Publication date
RU2014145544A (ru) 2016-06-10
SG10201608577RA (en) 2016-12-29
AU2013245878B2 (en) 2017-10-12
IL282732A (en) 2021-06-30
RS55690B1 (sr) 2017-07-31
KR20250005505A (ko) 2025-01-09
HUE045353T2 (hu) 2019-12-30
DK3628670T3 (da) 2022-12-05
KR102744039B1 (ko) 2024-12-17
EP3628670A1 (en) 2020-04-01
LT2836491T (lt) 2017-03-27
AU2018200168A1 (en) 2018-02-01
IL296199B1 (en) 2024-08-01
MX2014012380A (es) 2015-07-23
AU2013245878A1 (en) 2014-10-30
JP2015512942A (ja) 2015-04-30
PL3184523T3 (pl) 2019-12-31
WO2013155317A1 (en) 2013-10-17
US11491163B2 (en) 2022-11-08
DK2836491T3 (en) 2017-03-06
RS59392B1 (sr) 2019-11-29
EP2836491A4 (en) 2015-09-16
US20230140327A1 (en) 2023-05-04
EP2836491A1 (en) 2015-02-18
IL266165A (en) 2019-06-30
ES2745016T3 (es) 2020-02-27
RU2658911C2 (ru) 2018-06-26
PT2836491T (pt) 2017-02-08
EP3184523A1 (en) 2017-06-28
KR20220123339A (ko) 2022-09-06
EP3628670B1 (en) 2022-10-12
IL266165B (en) 2021-06-30
PT3628670T (pt) 2022-12-02
JP2018002742A (ja) 2018-01-11
IL282732B (en) 2022-12-01
US10245269B2 (en) 2019-04-02
AU2018200168B2 (en) 2019-08-29
PT3184523T (pt) 2019-09-26
SMT201900501T1 (it) 2019-11-13
EP4190777A1 (en) 2023-06-07
US12251386B2 (en) 2025-03-18
CN104603130A (zh) 2015-05-06
US20180243316A1 (en) 2018-08-30
LT3184523T (lt) 2020-02-10
EP2836491B1 (en) 2016-12-07
US20190269692A1 (en) 2019-09-05
SI3184523T1 (sl) 2020-04-30
PL3628670T3 (pl) 2023-02-20
IL296199B2 (en) 2024-12-01
PL2836491T3 (pl) 2017-08-31
ES2931316T3 (es) 2022-12-28
HUE060881T2 (hu) 2023-04-28
US20170143729A1 (en) 2017-05-25
NZ700761A (en) 2016-09-30
CA2870005C (en) 2021-06-22
HRP20170295T1 (hr) 2017-04-21
CN108358899B (zh) 2021-07-27
US20210137936A1 (en) 2021-05-13
JP2018199740A (ja) 2018-12-20
DK3184523T3 (da) 2019-08-19
CY1119383T1 (el) 2018-02-14
SMT201700132T1 (it) 2017-05-08
EP3184523B1 (en) 2019-06-19
CY1122883T1 (el) 2022-03-24
ES2617379T3 (es) 2017-06-16
SG10201912109QA (en) 2020-02-27
BR112014025508B1 (pt) 2020-11-17
CA2870005A1 (en) 2013-10-17
KR20150002730A (ko) 2015-01-07
US10821113B2 (en) 2020-11-03
US9872862B2 (en) 2018-01-23
IL296199A (en) 2022-11-01
IL235045A0 (en) 2014-12-31
SG11201406468YA (en) 2015-01-29
IL282732B2 (en) 2023-04-01
MX384641B (es) 2025-03-14
IN2014DN09068A (enExample) 2015-05-22
JP6634058B2 (ja) 2020-01-22
KR102120883B1 (ko) 2020-06-09
IL235045B (en) 2019-05-30
HUE031976T2 (en) 2017-08-28
HRP20191653T1 (hr) 2020-02-21
US20150065503A1 (en) 2015-03-05
MX362339B (es) 2019-01-11
US9394283B2 (en) 2016-07-19
SI2836491T1 (sl) 2017-06-30
CN108358899A (zh) 2018-08-03
CN104603130B (zh) 2018-04-27
US20250268905A1 (en) 2025-08-28
KR20200066380A (ko) 2020-06-09
KR102438340B1 (ko) 2022-08-30

Similar Documents

Publication Publication Date Title
US12251386B2 (en) Salt form of a human histone methyltransferase EZH2 inhibitor
HK40087682A (en) Hbr salt form for ezh2 inhibition
HK40026825B (en) Salt form for ezh2 inhibition
HK40026825A (en) Salt form for ezh2 inhibition

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20151126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20161130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171012

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171204

R150 Certificate of patent or registration of utility model

Ref document number: 6255382

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250